Fact-checked by Grok 2 weeks ago

Zeneca

Zeneca Group PLC was a multinational corporation focused on the research, development, manufacture, and marketing of pharmaceuticals, agrochemicals, and specialty chemicals. Formed in 1993 through the demerger of (ICI)'s life sciences and specialty products divisions, it operated as an independent entity headquartered in until its merger with Sweden's in 1999, creating the global biopharmaceutical giant . During its six years of independence, Zeneca emphasized innovation in oncology and other therapeutic areas, launching several blockbuster drugs that advanced cancer treatment. Notable products included Zoladex (goserelin), a hormone therapy for prostate and breast cancers; Casodex (bicalutamide), an oral anti-androgen for prostate cancer; and Nolvadex (tamoxifen), a pioneering selective estrogen receptor modulator for breast cancer prevention and treatment. The company also maintained a strong presence in agrochemicals, developing crop protection solutions, and expanded through strategic acquisitions, such as full ownership of U.S.-based Salick Health Care in 1997 to integrate oncology services. By the time of the merger, Zeneca's pharmaceutical portfolio generated significant revenue, with sales of approximately £6.3 billion annually (as of 1998), positioning it as a leader in global healthcare innovation. The 1999 merger with , valued at approximately $67 billion (£41 billion), combined Zeneca's strengths in and agrochemicals with Astra's expertise in gastrointestinal and cardiovascular therapies, forming a unified entity with enhanced R&D capabilities and a broader product . This strategic alliance, completed on April 6, 1999, resulted in PLC, where former Zeneca shareholders held a 53.5% stake, and the company continued to build on Zeneca's legacy in delivering life-changing medicines worldwide.

Origins and Formation

Background in Imperial Chemical Industries

Imperial Chemical Industries (ICI) was established in 1926 through the merger of four leading British chemical firms: Nobel Industries Ltd., Brunner, Mond and Company Ltd., United Alkali Company Ltd., and British Dyestuffs Corporation. This consolidation created a powerhouse focused primarily on dyes, explosives, and fertilizers, aiming to compete with international giants like Germany's and the ' DuPont. By pooling resources, ICI rapidly expanded production capacity, including a major £20 million ammonia-soda plant at for fertilizers, positioning it as Britain's largest manufacturer and a cornerstone of the national economy. ICI's venture into pharmaceuticals began in the mid-1930s, driven by its Dyestuffs Division's expertise in . Responding to competitive pressures from companies such as and Hoechst, ICI formed a Medicinal Chemicals Section to explore therapeutic applications, leading to early developments in drugs for bacterial and parasitic infections, as well as anesthetics like (Fluothane). A dedicated Pharmaceuticals Division was formalized in the , building on wartime penicillin production processes and marking a shift toward high-value life sciences. Meanwhile, the sector originated with the 1937 formation of Plant Protection Ltd. as a with Cooper, McDougall & Robertson, which ICI fully acquired by 1953; this unit advanced research at facilities like Jealott's Hill, introducing innovations such as the (Gammexane) in the 1930s and the selective herbicide in 1945. From the 1950s through the , ICI's pharmaceutical and agrochemical operations experienced robust growth, fueled by groundbreaking innovations that established global leadership. In pharmaceuticals, the division pioneered beta-blockers, including (Inderal) in 1965, developed by James Black at ICI's Alderley Park labs, which transformed treatments for and by selectively blocking adrenaline effects on the heart. Other key advances included atenolol (Tenormin) and the anti-cancer drug (Nolvadex). Agrochemicals complemented this with herbicides like ioxynil and the contact herbicide (Gramoxone) in the 1960s, enhancing crop protection amid post-war agricultural intensification. These sectors achieved strong performance, with pharmaceuticals attaining profit margins of around 30% by the and , while agrochemicals benefited from rising demand for efficient pesticides and fertilizers. By the late 1980s and early 1990s, ICI grappled with mounting financial strains from aggressive acquisitions, including the 1985 purchase of Beatrice's specialty chemicals businesses and the 1990 full acquisition of Tioxide, which saddled the company with approximately £3 billion in debt amid volatile commodity markets and declining bulk chemicals profitability. Overall group profits fell sharply—trading profits in core non-bioscience areas turned to losses—prompting a comprehensive strategic review under CEO Denys Henderson. The pharmaceuticals and agrochemicals divisions, reorganized as the biosciences group, generated trading profits of £587 million in 1992, representing about 40% of the company's overall profitability despite the conglomerate's undervaluation of their growth potential, thus motivating the separation of these high-margin units to unlock shareholder value.

Demerger from ICI

In July 1992, (ICI) announced plans to demerge its pharmaceuticals, agrochemicals, and specialties businesses to create a separate entity focused on biosciences, allowing the remaining ICI to concentrate on its core chemicals and paints operations. The decision, led by ICI chairman Sir Denys Henderson, aimed to unlock amid competitive pressures and a threat from Hanson PLC earlier that year. Zeneca was legally structured as a and officially from ICI on June 1, 1993, with ICI shareholders receiving one Zeneca share for each ICI share held. The included a £1.3 billion by Zeneca to fund operations, resulting in an initial of approximately £5.5 billion for the new company. Headquartered in , , Zeneca listed on the London Stock Exchange (ticker: ZN) and (ticker: ZN) from its first day of trading. The name "Zeneca" was an invented term developed by the branding consultancy Interbrand in 1992, selected from options that met specific criteria: beginning with the letter Z (to appear at the top or bottom of alphabetical lists), being phonetically memorable, consisting of no more than three syllables, and carrying no offensive connotations in any major language. Sir Denys Henderson served as Zeneca's initial chairman, with the board prioritizing the integration of the former ICI pharmaceuticals and agrochemicals divisions into cohesive operations under the Zeneca Pharma and Zeneca Agrochemicals units. The process involved transferring over 30,000 employees from ICI to Zeneca, alongside the allocation of manufacturing facilities, research sites, and . Early challenges included resolving asset valuation disputes between the two entities, which were settled by mid-1993 through approvals and regulatory clearances, enabling Zeneca to commence independent operations.

Corporate Development

Acquisitions and Divestitures

Following its demerger from Imperial Chemical Industries in 1993, Zeneca pursued a series of acquisitions and divestitures to refine its portfolio, emphasizing growth in pharmaceuticals and agrochemicals while divesting non-core assets. This strategy facilitated expansion into key markets like the United States and Europe. In December 1994, Zeneca acquired a 50% stake in Salick Health Care, a U.S.-based operator of oncology clinics, for $195 million in cash, with an option to purchase the remaining shares that valued the entire company at more than $440 million. This move marked Zeneca's entry into integrated cancer care services, complementing its pharmaceutical offerings. By May 1996, Zeneca sold its textile colors to for an undisclosed amount, reported as up to £150 million (approximately $230 million at the time), allowing the company to redirect resources toward its core pharmaceutical and agrochemical operations. The divestiture eliminated a underperforming segment and streamlined Zeneca's chemical portfolio. In 1997, Zeneca exercised its option to acquire the remaining 50% of for approximately $234 million, achieving full ownership and integrating the network of facilities into its operations. This completed the strategic expansion into U.S. healthcare delivery. Zeneca further strengthened its agrochemical division in December 1997 by purchasing the U.S. fungicide operations of Japan's Ishihara Sangyo Kaisha, along with international distribution rights to four new products, for $500 million. The acquisition enhanced Zeneca's position in crop protection pesticides, particularly in North American markets. In November 1998, ahead of its merger with , Zeneca announced plans to divest its Zeneca Specialties division, encompassing fine chemicals, biocides, and industrial colors, to heighten focus on high-growth areas in pharmaceuticals and . The unit, with 1998 sales of about $1.1 billion, was ultimately sold in 1999 for $2.1 billion, but the decision underscored Zeneca's ongoing portfolio rationalization.

Leadership and Organizational Changes

Upon its formation in 1993 through the from (ICI), Zeneca was led by Sir Denys Henderson as chairman and Sir David Barnes as . Henderson, who had chaired ICI during the demerger process, guided the new entity's initial setup and strategic independence before stepping down in 1995. Barnes, a by training with extensive experience in ICI's bioscience operations, remained CEO until 1999, overseeing the company's growth in pharmaceuticals and agrochemicals while navigating market challenges. Tom McKillop, initially chief executive of the pharmaceuticals division since 1994, joined the group board as an in 1996, positioning him for broader responsibilities ahead of the 1999 merger. The board was predominantly , featuring executive directors from key divisions and non-executive members with international expertise. By 1997, it incorporated additional non-executive directors with pharmaceutical expertise, including Jonathan Symonds as finance director, to support strategic preparations amid industry consolidation. Organizationally, Zeneca structured itself into three core divisions—pharmaceuticals, , and specialties—upon launch in 1993, reflecting its bioscience focus. This framework persisted through 1995, when the company achieved full operational capacity across segments. Under Barnes' direction, leadership prioritized R&D expansion, with emphasis on integration to drive innovation. This shift marked a from ICI's diversified model to a leaner, research-oriented approach.

Business Operations

Pharmaceutical Division

Zeneca's Pharmaceutical Division centered on human healthcare, developing and commercializing prescription medicines for serious diseases. Following the 1993 demerger from ICI, the division generated approximately £1.6 billion in revenue in 1992 (the last full year under ICI), accounting for about 40% of the group's total sales of £4 billion. By 1998, pharmaceutical sales had expanded to around £4.9 billion, driven by growth in key markets such as oncology and cardiovascular therapeutics, contributing to overall group sales of £7.6 billion. The division invested heavily in , allocating £500-700 million annually during the to advance innovative therapies. These efforts were concentrated at major sites in and the , with a focus on emerging fields like and monoclonal antibodies to address unmet needs in cancer and other chronic conditions. R&D expenditure reached about £843 million in 1998 for the group, supporting a pipeline that emphasized targeted treatments and biologic approaches. Globally, the division operated in more than 75 countries, with significant manufacturing facilities in , —serving as a key hub for production and packaging—and , in the , which supported North American operations. Strategic partnerships with academic institutions, including the , facilitated collaborative research in areas like and during the 1990s. These alliances enhanced innovation and accelerated the translation of basic science into clinical applications. Regulatory achievements marked progress in the division's pipeline, including FDA entry into trials for (Faslodex) in 1995, a novel downregulator for . The emphasis on and cardiovascular clinical trials underscored Zeneca's commitment to high-impact areas, with multiple applications advancing through phases. These milestones positioned the division for future approvals and market expansions. By 1997, the Pharmaceutical Division employed around 20,000 people worldwide, with initiatives to promote in teams. These efforts aimed to ensure inclusive in trials, reflecting a growing recognition of the need for equitable healthcare outcomes across demographics. The workforce supported operations from to , fostering a culture of scientific excellence.

Agrochemical Division

The Agrochemical Division of Zeneca was a leading global provider of crop protection products, specializing in pesticides, herbicides, fungicides, and insecticides designed to enhance agricultural yields and food quality. Formed as part of the 1993 demerger from , the division quickly established itself as a core pillar of Zeneca's operations, contributing significantly to the company's early growth through innovative formulations and broad . By focusing on high-performance active ingredients, it addressed key challenges in pest management and across diverse cropping systems. The division faced regulatory challenges, including EU reviews under Directive 91/414/EEC for active substance approvals, prompting investments in lower-residue formulations. Financially, the division's sales stood at approximately £1.5 billion in 1994, representing about 30-40% of Zeneca's overall at the time, and grew steadily to a peak of £1.8 billion in 1996 before stabilizing at £1.7 billion in 1998 amid competitive pressures and currency fluctuations. This performance underscored the division's resilience in a maturing market, with operating profits reaching £224 million in 1996 and R&D investments exceeding £160 million annually by the late 1990s to support pipeline development. Global sales reached over 100 countries, with particularly strong performance in , where regulatory familiarity aided gains, and in regions benefiting from expanding agricultural demand. Key research and development activities were centered at the Jealott's Hill Research Station in the , a historic facility dating back to ICI's era, which served as the hub for discovering new active ingredients and conducting efficacy trials. Additional innovation sites included facilities in , for biotechnology integration. Product categories emphasized herbicides such as the Fusilade line for grass weed control in broadleaf crops, insecticides like for broad-spectrum pest protection, and fungicides including Amistar, which became a product with sales of approximately £178 million ($294 million) in due to its efficacy against diseases like and . These offerings were complemented by veterinary pharmaceuticals targeted at health, including parasiticides to support animal productivity in farming operations. Field trials were routinely conducted in major agricultural regions, such as the U.S. Midwest, plains, and Asian belts, to validate performance under local conditions. Strategically, following the 1996 divestiture of non-core assets like textiles from the broader group, shifted toward sustainable solutions, integrating lower-dose formulations and precision application technologies to reduce environmental footprints. This era saw increased collaborations with firms, including the 1997 acquisition of Mogen International for expertise in genetically modified seeds and traits, enabling a "whole strategy" that combined chemical protections with enhancements for traits like herbicide tolerance. By 1998, over 50 partnerships with academic and industrial entities supported advancements in output traits, such as improved varieties. On environmental and regulatory fronts, the division maintained strict compliance with pesticide directives, such as Directive 91/414/EEC, which governed registration and of active substances. In 1998, Zeneca launched (IPM) programs promoting reduced chemical use through biological and cultural controls, exemplified by Amistar's profile of lower toxicity and minimal residue persistence compared to older fungicides. These initiatives aligned with growing demands for eco-friendly agriculture, helping to mitigate regulatory scrutiny while enhancing product acceptance. The division employed around 8,000 staff worldwide by 1998, with a significant portion dedicated to sales, , and on-site trials in key farming areas.

Key Products and Innovations

Oncology Portfolio

Zeneca's oncology portfolio centered on therapies for and cancers, leveraging products inherited from (ICI) and new developments during its independent years. Key offerings included Nolvadex (tamoxifen), inherited from ICI and approved by the FDA in 1977 for treating advanced , which became a cornerstone of the company's pharmaceutical revenue in the as a widely prescribed . (goserelin), also inherited from ICI and launched in 1985 initially in the UK and later approved in the , served as a (GnRH) agonist delivered via subcutaneous implant to suppress testosterone production in patients and in cases, providing sustained hormone deprivation over months. Complementing these, (bicalutamide), a developed by Zeneca, received US FDA approval in 1995 for use in combination with a luteinizing hormone-releasing hormone analog like Zoladex to treat advanced by blocking receptors. Development of Zoladex focused on its role as a long-acting depot formulation, enabling monthly or quarterly dosing to achieve by downregulating GnRH receptors and reducing serum testosterone to castrate levels within 2-4 weeks of initiation. Clinical trials, such as a randomized study involving radiotherapy combined with , demonstrated improved local control and overall survival in patients with locally advanced , with the combined regimen showing a statistically significant over radiotherapy alone at 5-year follow-up. These trials highlighted Zoladex's efficacy in advanced cases, where it contributed to better when integrated into multimodal treatment protocols. By the late 1990s, oncology products accounted for a substantial portion of Zeneca's pharmaceutical sales, driven by strong demand for breast and prostate cancer therapies amid rising incidence rates. The company expanded its reach through the acquisition of Salick Health Care in 1997, integrating specialized cancer treatment centers to offer comprehensive care including chemotherapy administration and supportive services. Innovations in the portfolio included advancements in aromatase inhibitors, with Arimidex (anastrozole), developed by Zeneca and FDA-approved in 1995 as second-line therapy for advanced breast cancer in postmenopausal women, showing superiority over megestrol acetate in clinical trials. By the late 1990s, Arimidex was in Phase III trials (e.g., ATAC) evaluating its role in adjuvant therapy. However, the portfolio faced challenges from impending patent expirations, notably for Nolvadex, whose US exclusivity was upheld until August 2002, after which generic entry was anticipated to erode and revenues. This looming loss underscored the need for pipeline progression, as remained a high-growth area but required sustained to offset revenue declines from mature products.

Cardiovascular and Other Therapeutics

Zeneca's cardiovascular portfolio centered on established therapies for , , and post- care, with Tenormin (atenolol), inherited from ICI and introduced in 1976, serving as a flagship cardioselective beta-blocker. Tenormin works by selectively blocking beta-1 adrenergic receptors in the heart, reducing and while minimizing effects on bronchial , making it suitable for patients with respiratory comorbidities. Clinical studies demonstrated its efficacy in secondary prevention after acute myocardial infarction, with beta-blockers like atenolol associated with a 15-25% reduction in mortality risk in the early post-infarction period. By , Tenormin generated approximately $450 million in global sales, contributing to the cardiovascular segment's overall performance. Complementing Tenormin, Zestril (lisinopril), an () inhibitor licensed and marketed by Zeneca since the early , targeted and by inhibiting the conversion of I to II, thereby promoting and reducing cardiac workload. Sales of Zestril reached $1,126 million in 1998, underscoring its role as a leading in the U.S. market where it became the most prescribed in its class by the late . Zeneca emphasized combination therapies, such as Zestoretic (lisinopril with hydrochlorothiazide), to enhance efficacy in resistant cases. The cardiovascular category collectively accounted for about 16-23% of Zeneca's pharmaceutical revenues in 1998, totaling around $2,074-3,017 million, reflecting its strategic importance amid growing demand for chronic disease management. In respiratory therapeutics, Accolate (zafirlukast), a approved by the FDA in September 1996, represented Zeneca's innovation in management by blocking cysteinyl s to reduce and . It was positioned as an oral to inhaled corticosteroids for mild-to-moderate persistent , with 1998 sales of $152 million signaling early market adoption. Beyond core cardiovascular and respiratory areas, Zeneca expanded into with Diprivan (), an intravenous sedative-hypnotic for induction and maintenance of general , which achieved $653 million in sales by 1998 but faced a notable FDA dispute in 1999 over generic approvals using preservatives like , leading to legal challenges from Zeneca regarding and safety. Zeneca's broader therapeutics included forays into (CNS) disorders, with early investments in antipsychotics like Seroquel (), launched in 1997 and generating $66 million in initial sales, alongside exploratory research into neurodegenerative conditions such as during the late 1990s. Anti-infectives, exemplified by Merrem (), contributed $128 million in 1998 through hospital-based treatments for severe bacterial infections. Niche areas like were supported by ancillary products, though specific revenues were modest, collectively amounting to around £200 million across specialized therapeutics by 1998. The pipeline featured Phase II candidates for enhanced control, aiming to sustain the cardiovascular post-patent challenges.

Merger and Dissolution

Negotiations and Merger with Astra

In the late 1990s, , a pharmaceutical company focused on expanding its presence, engaged in preliminary discussions with Zeneca Group PLC that laid the groundwork for a major consolidation in the industry. These initial talks, which began around 1997 amid rumors of potential partnerships, evolved into formal negotiations by late 1998 as both firms sought to enhance their competitive position against larger U.S.-based rivals. On December 9, 1998, the companies announced an all-stock merger of equals valued at approximately $67 billion (£41 billion at the time), creating one of Europe's largest cross-border deals. Under the terms, shareholders would receive about 0.54 new shares for each share, resulting in holders owning 46.5% of the combined entity while Zeneca shareholders retained 53.5%. The negotiations were led by key executives including Tom McKillop, Zeneca's chief executive, and Håkan Mogren, Astra's president and CEO, who emphasized the strategic alignment between the two firms. A significant point of agreement was the location of the corporate headquarters in , , to leverage Zeneca's established base, while maintaining major research and development operations in , , and allocating several board seats to Swedish representatives to reflect the merger's balanced nature. The deal positioned the new AstraZeneca PLC as a global leader with 1997 sales exceeding $15 billion and a robust pipeline, enabling greater investment in innovation. The merger's rationale centered on complementary portfolios that would broaden therapeutic expertise and market reach: Astra's strengths in gastrointestinal and respiratory medicines paired well with Zeneca's focus on oncology and cardiovascular drugs, reducing overlap and accelerating product development. Executives projected annual pre-tax cost synergies of $1.1 billion (£700 million) by the third year post-merger, primarily through streamlined operations, shared R&D, and optimized sales forces, without compromising growth initiatives. Antitrust scrutiny followed, with the European Commission approving the transaction on February 18, 1999, after determining it would not harm competition, and the U.S. Federal Trade Commission granting clearance on March 25, 1999, subject to divestitures of certain overlapping assets like levobupivacaine to address concerns in anesthesia markets. Shareholder approval proceeded smoothly, with Zeneca investors voting overwhelmingly in favor in February 1999—reported as near-unanimous support exceeding 99%—reflecting confidence in the deal's value creation. The announcement triggered a positive response, with Zeneca's price surging approximately 20% in the days following the disclosure, underscoring enthusiasm for the enhanced scale and synergies. Astra shareholders similarly endorsed the merger at their April 1999 meeting, paving the way for the entity's formal establishment on April 6, 1999.

Transition to AstraZeneca and Legacy

The merger of and Zeneca Group PLC was completed on April 6, 1999, resulting in the formation of PLC, with Zeneca shares delisted from the London Stock Exchange shortly thereafter. Tom McKillop, previously CEO of Zeneca, assumed the role of CEO for the new entity, while Sir Denys Henderson, former chairman of Zeneca, served as chairman of until 2001. This leadership transition ensured continuity in strategic direction, emphasizing the integration of complementary R&D capabilities from both companies. Post-merger integration focused on streamlining operations to achieve projected synergies, including the of R&D sites and of redundant facilities. Key decisions on site rationalization were finalized by mid-1999, leading to the elimination of overlapping functions and a one-time charge of $864 million for integration costs, including $379 million in manpower-related expenses. These efforts were expected to deliver annual cost savings of $1.1 billion by the third year, primarily through reduced administrative and R&D overheads. The combined R&D pipeline was accelerated, notably advancing the development of (branded as Crestor), a licensed from & Co. and originally in Astra's portfolio, which received approval in 2002 and U.S. FDA approval in 2003, contributing to AstraZeneca's cardiovascular franchise growth. Zeneca's legacy products, particularly in , formed a cornerstone of AstraZeneca's early portfolio. Zoladex (goserelin), a for and developed under Zeneca, generated $734 million in global sales in 2000 alone and remained a steady performer, with annual revenues exceeding $1 billion in the mid-2000s before stabilizing around $800-1,000 million through the . Cumulatively, Zoladex and other Zeneca-derived oncology assets like Casodex contributed over $5 billion in sales from 2000 onward, establishing AstraZeneca as a leader in hormone therapies and supporting the company's , which grew to represent a significant portion of total sales by the early 2000s. The of Zeneca from (ICI) in 1993 served as a pioneering model for pharmaceutical , demonstrating how separating high-growth life sciences from commoditized chemicals could unlock and focus management on innovation-driven sectors. This approach influenced subsequent industry restructurings, such as the of focused pharma units from diversified conglomerates in the late 1990s and 2000s. Zeneca's agrochemical division, emphasizing early sustainable practices like , was carried forward into the 2000 of AG, formed by merging Zeneca Agrochemicals with Novartis's crop protection and seeds businesses. , valued at $7.9 billion in combined 1998 sales at formation, adopted and expanded these practices, prioritizing lower-impact crop solutions that aligned with emerging regulatory demands for . Zeneca's culture of innovation, rooted in its R&D investments, laid the groundwork for AstraZeneca's ascent to a top-10 global pharmaceutical company by the early . Key patents from Zeneca's era, including those underpinning Zoladex and advancements in formulations, provided royalty streams and defensive that supported sustained growth. This innovative ethos, combined with Astra's strengths, fostered a collaborative environment that propelled AstraZeneca's , evidenced by multiple launches in the decade following the merger. In 1998, Zeneca reported annual sales of £5.5 billion and pretax profits of £1.1 billion, reflecting robust performance in pharmaceuticals and agrochemicals that positioned the company for the merger. These figures established a strong financial foundation, enabling to achieve 2000 revenues of $15.8 billion (approximately £11 billion at prevailing exchange rates), an 8% increase from 1999 results, and operating profits of $4.0 billion.

References

  1. [1]
    A timeline of our company history - AstraZeneca
    AstraZeneca was founded in 1999 through the merger of Sweden's Astra AB and the UK's Zeneca Group PLC. This strategic merger combined each company's ...
  2. [2]
    A history of AstraZeneca - pharmaphorum
    Sep 18, 2020 · Zeneca Group plc​​ British multinational pharma company Zeneca was formed by a demerger of the pharmaceuticals and agrochemicals businesses of ...
  3. [3]
    History of Imperial Chemical Industries PLC - FundingUniverse
    1926: Four major chemical companies in Great Britain merge to become Imperial Chemical Industries (ICI): Nobel Industries Ltd.; Brunner, Mond and Company Ltd.; ...
  4. [4]
    Celebrating ICI - SCI
    The Dyestuffs division started research into pharmaceuticals in the mid-1930s when it set up a Medicinal Chemicals Section. This was in response to the ...
  5. [5]
    [PDF] Herbicide Company “Genealogy” - College of Agricultural Sciences |
    Some companies have a distinguished herbicide history but no longer develop new herbicides. These are so noted. Numerous companies and individuals have been ...Missing: 1950s- | Show results with:1950s-
  6. [6]
    Propranolol: A 50-Year Historical Perspective - PMC - PubMed Central
    The invention of the beta-adrenergic receptor antagonist, propranolol, by Sir James Black in the 1960s revolutionized the treatment of cardiovascular diseases.
  7. [7]
    How competition ate away Britain's chemicals giant | Business
    Jun 24, 2007 · The bell is tolling for ICI, the once mighty Imperial Chemical Industries ... But debt hit £3bn, almost the same as the company's market ...
  8. [8]
    ICI to go ahead with split, cut 9,000 jobs - UPI Archives
    Feb 25, 1993 · ICI said trading profit before one-off restructuring charges at the Zeneca business fell to 587 million pounds ($839 million) in 1992, compared ...
  9. [9]
    ICI launches pounds 1.3bn rights issue in run-up to the big split
    May 13, 1993 · Smith New Court is forecasting pounds 583m pre-tax profits for Zeneca in the current year, up from pounds 102m - after pounds 304m of ...
  10. [10]
    Why ICI Chose to Demerge
    At the start of the 1990s, ICI, like other companies with a similar problem, faced the indignity of a takeover threat.
  11. [11]
    ICI's major M&A deals - Reuters
    Aug 9, 2007 · June 1, 1993 - ICI spins off its Zeneca bioscience arm in Britain's biggest corporate demerger, along with a massive 1.3 billion pounds ...Missing: profits | Show results with:profits
  12. [12]
    ICI/Zeneca: Structure of the demerger | Practical Law
    At the end of February, ICI formally announced that it would be asking shareholders to approve the demerger of its bio-science business to a newly formed ...
  13. [13]
    https://www.the-independent.com/news/business/ici-launches-pounds-1-3bn-rights-issue-in-runup-to-the-big-split-next-month-s-zeneca-demerger-will-create-two-worldclass-companies-says-chairman-as-grey-market-in-the-shares-begins-2322627.html
  14. [14]
    Zeneca - Wikipedia
    Zeneca (officially Zeneca Group PLC) was a British multinational pharmaceutical company headquartered in London, United Kingdom.
  15. [15]
    ASTRAZENECA PLC AZN Our story - London Stock Exchange
    Issuer Market Cap £m. 385,101.92. Admission date. 01 June 1993. Country of Incorporation. GB. Information provided by ASTRAZENECA PLC. Media from AstraZeneca ...Missing: Zeneca initial
  16. [16]
    Posts incorrectly interpret intended meaning of 'AstraZeneca' - Reuters
    Apr 19, 2021 · A mistranslation of “AstraZeneca”, the name of a pharmaceutical company making one of the COVID-19 vaccines, is being disseminated online.Missing: 1992 | Show results with:1992
  17. [17]
    Zeneca Group PLC | Encyclopedia.com
    Historical Background​​ Zeneca Group PLC is the result of what has come to be called a “demerger” from Imperial Chemical Industries (ICI), one of the United ...
  18. [18]
    Zeneca Group to Purchase 50% Stake in Salick Health : Health care
    Dec 23, 1994 · The deal creates an unusual partnership between Zeneca, a leading maker of cancer drugs, and Los Angeles-based Salick Health, which operates ...
  19. [19]
    Zeneca sells loss-making dye business for pounds 150m
    May 9, 1996 · Zeneca, the drugs group, is to sell its textile colours business to the German group BASF for up to pounds 150m. The intention to dispose of ...Missing: colors | Show results with:colors
  20. [20]
    Zeneca to Buy Remaining Stake of Salick - Los Angeles Times
    British drug maker Zeneca Group said Thursday that it will pay about $234 million to acquire the 50% of Los Angeles-based cancer treatment specialists ...
  21. [21]
    https://www.latimes.com/archives/la-xpm-1994-12-23-fi-12269-story.html
  22. [22]
    https://www.the-independent.com/news/business/zeneca-sells-lossmaking-dye-business-for-pounds-150m-1346377.html
  23. [23]
    Sir Denys Henderson obituary | ICI - The Guardian
    May 26, 2016 · Denys Henderson, who has died aged 83, was the man who oversaw the brave decision to break Britain's best known industrial icon, ICI, into two.Missing: 1993-1999 | Show results with:1993-1999
  24. [24]
    Denys Henderson, industrialist who split up ICI, 1932-2016
    May 27, 2016 · Following the demerger, he served two years as chairman of both ICI and Zeneca and then left the company. The units are now respectively part of ...Missing: 1993-1999 | Show results with:1993-1999
  25. [25]
    Sir David Barnes obituary | AstraZeneca - The Guardian
    Apr 23, 2020 · Sir David Barnes, who has died aged 84, was the self-effacing but determined and clear-sighted chief executive who turned the bioscience interests of ICI into ...
  26. [26]
    Sir David Barnes, veteran of ICI who helped to found the pharma ...
    Apr 11, 2020 · He was deputy chairman of Astra Zeneca from 1999 until his retirement in 2001. James David Francis Barnes was born on March 4 1936 in ...
  27. [27]
    [PDF] ~ENECA - FBcoverup.com
    Jun 17, 1993 · Pharmaceuticals' 1992 trading profit before exceptional items declined by 9 percent. from. £536 million in 1991 to £488 million, due mainly ...
  28. [28]
    McKillop, Tom 1943– | Encyclopedia.com
    McKillop was appointed chief executive officer of Zeneca Phamaceuticals in 1994, and two years later became executive director of Zeneca Group. ZENECA ...
  29. [29]
    AstraZeneca PLC: Governance, Directors and Executives ...
    Bo Angelin. Director/Board Member, 24/07/2007, - ; Jonathan Symonds. Director of Finance/CFO, 30/09/1997, 30/06/2007 ; Erna Möller. Director/Board Member, 05/04/ ...
  30. [30]
    Zeneca Buying Astra as Europe Consolidates - The New York Times
    Dec 10, 1998 · In one of Europe's biggest mergers, the Zeneca Group P.L.C. of Britain announced a stock deal valued around $35 billion today to buy Astra ...
  31. [31]
    Investment: Zeneca profits slip to pounds 1.1bn | The Independent
    Feb 18, 1999 · Zeneca sales also suffered a pounds 208m blow due to the strong pound, ending 1998 at pounds 5.5bn, 6 per cent up on the previous year. Sir ...
  32. [32]
    Zeneca, Astra agree to merge: bidding war seen likely 12-09-98
    Dec 9, 1998 · Zeneca and Astra have boasted that together, they will have R&D expenditure of $1.9 billion -- making it the world's third largest in R&D terms.
  33. [33]
    [PDF] AstraZeneca Pro Forma Combined 1998 Results - Hugin Online
    Jan 21, 1999 · a) in connection with the consummation of the Merger, AstraZeneca is required to pay to Merck (i) a lump sum of approximately $740 million (£446 ...
  34. [34]
    [PDF] Zeneca Group PLC1
    “Annual Report and Form 20-F”, 1998: page 23. Zeneca Group Plc, Page 1. Zeneca Group PLC1. In March 1999, Steve Hawkins had been assigned ...
  35. [35]
    Our UK Sites | AstraZeneca UK
    AstraZeneca Macclesfield is a science, technology and manufacturing hub and home to c.5,200 people. It is the second largest manufacturing site in the ...Missing: Wilmington | Show results with:Wilmington
  36. [36]
    AstraZeneca - Wikipedia
    Its British counterpart, Zeneca PLC was formed in 1993 when ICI divested its ... AstraZeneca has one of the highest market capitalisations of pharmaceutical ...
  37. [37]
    T 1680/17 (Fulvestrant/ASTRAZENECA) 24-01-2019 | epo.org
    Jan 24, 2019 · In 1995, document (5) disclosed a monthly castor oil-based formulation (page 29, right column). In 1996, document (4) was published, followed in ...
  38. [38]
    ICI 182780 (Faslodex): development of a novel, "pure" antiestrogen
    ICI 182780 specifically down-regulates the estrogen receptor and, thus, represents the first of a new class of therapeutic agents.Missing: 1995 | Show results with:1995
  39. [39]
    [PDF] Zeneca Agrochemicals - AgBioForum
    Table 1 gives the key financial figures for Zeneca Agrochemicals and table 2 presents the company's sales by main pesticides group. Approximately 7,000 ...Missing: history 1993-1999
  40. [40]
    [PDF] 1999 Annual Report - ddd-UAB
    AstraZeneca's R&D expenditure increased by. 18% in 1999 to $2,923 million ... 1998, Zeneca moved to dismiss, or alternatively stay, Monsanto's Missouri ...
  41. [41]
    Zeneca profits up 42% in first year after demerger: Volume and price ...
    Pharmaceutical trading profits were up 21 per cent at pounds 589m, agrochemical profits rose 1 per cent to pounds 86m and speciality chemicals, which are highly ...Missing: 1992 | Show results with:1992
  42. [42]
    50th ANNIVERSARY OF THE FIRST CLINICAL TRIAL WITH ICI ...
    With Lois Trench's success for FDA approval on 31st December 1977, orders for the export of tamoxifen to the USA started to climb.
  43. [43]
    [PDF] 19726-S024 Zoladax 3.6mg Depot, and 10.8 Depot Medical Review
    Apr 19, 1996 · On January 11, 1996, Zeneca received approval for a 10.8 mg, 3-month depot formulation of ZOLADEX® for the same indication.
  44. [44]
    [PDF] Bicalutamide Tablets USP - accessdata.fda.gov
    What are bicalutamide tablets? Initial U.S. Approval: 1995. Evaluate for clinical progression if to four months of treatment. Hepatitis or marked increases ...Missing: Zeneca | Show results with:Zeneca
  45. [45]
    Improved Survival in Patients with Locally Advanced Prostate ...
    Jul 31, 1997 · Adjuvant treatment with goserelin, when started simultaneously with external irradiation, improves local control and survival in patients with locally advanced ...
  46. [46]
    AstraZeneca Nolvadex Patent Valid Until 2002, Firm Says After ...
    Sep 25, 2000 · AstraZeneca expects that generic competition to Nolvadex will be limited to Barr's "authorized" tamoxifen until Aug. 20, 2002, following a ...
  47. [47]
    [PDF] Atenolol – 30 Years of Life Cycle Management
    • 1987 to 1990 - Peak sales / patent expiry in major markets. • 1993 - Zeneca ... • Tenormin® is still part of the AstraZeneca cardiovascular product portfolio.
  48. [48]
    [PDF] TENORMIN® (atenolol) Tablets Rx only - accessdata.fda.gov
    A significant beta-blocking effect of TENORMIN, as measured by reduction of exercise tachycardia, is apparent within one hour following oral administration ...Missing: attack | Show results with:attack
  49. [49]
    AstraZeneca divests rights to established hypertension medicines
    Jan 27, 2020 · AstraZeneca has agreed to sell the global commercial rights to Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose ...
  50. [50]
    Zafirlukast for Asthma | The Medical Letter Inc.
    Dec 20, 1996 · Zafirlukast (za fir loo kast; Accolate - Zeneca), the first leukotriene receptor anta-gonist approved by the US Food and Drug Administration ...
  51. [51]
    Zeneca, Incorporated, Plaintiff-appellant, v. Donna E. Shalala, in Her ...
    On January 4, 1999, the FDA approved Gensia's ANDA for propofol with Sulfite. On the same day, the FDA denied Zeneca's petition. The FDA noted that it "did ...Missing: dispute | Show results with:dispute
  52. [52]
    The Company File | Zeneca and Astra merge to form drug giant
    Drug companies Zeneca and Astra are planning to merge, forming a new company worth $67bn (£41bn), in one of the largest-ever European mergers.Missing: divestiture | Show results with:divestiture<|control11|><|separator|>
  53. [53]
    Astra, Zeneca To Merge - Bioprocess Online
    ... Tom McKillop (currently CEO of Zeneca's pharmaceuticals business) will be chief executive officer. Sir David Barnes (CEO of Zeneca Group plc) and Håkan ...Missing: appointed | Show results with:appointed<|control11|><|separator|>
  54. [54]
    https://law.justia.com/cases/federal/appellate-courts/F3/213/161/532646/
  55. [55]
    European Drug Companies To Merge - CBS News
    Dec 8, 1998 · Tom McKillop, currently the chief executive of Zeneca's pharma division, will become the chief executive of the merged company. In a ...
  56. [56]
    Tom McKillop 1943— Biography - Early career, Ici becomes zeneca
    Sir Thomas (Tom) McKillop presided over the 1999 merger of Zeneca Group—formerly ICI Pharmaceuticals—with Astra of Sweden, forming the new London-based company ...
  57. [57]
    [PDF] Case No COMP/M.1403 - ASTRA / ZENECA - European Commission
    Feb 18, 1999 · The result of that investigation has been confirmed in the current case, as the investigation indicates that there are arguments for defining ...
  58. [58]
    News in brief | Business - The Guardian
    Mar 1, 1999 · British shareholders overwhelmingly approved the deal, but Astra's are more dubious. A shareholder group representing about 10 per cent of the ...<|separator|>
  59. [59]
    https://www.referenceforbusiness.com/biography/M-R/McKillop-Tom-1943.html
  60. [60]
    INTERNATIONAL BRIEFS; Deal Is Completed By Astra and Zeneca
    Apr 7, 1999 · Shareholders of Astra, Swedish drug maker, approve company's combination with Zeneca of Britain; name of new company is AstraZeneca PLC (S)
  61. [61]
    https://www.theguardian.com/business/1999/mar/02/18
  62. [62]
    Sir Denys Henderson – obituary - The Telegraph
    May 30, 2016 · Sir Denys Henderson, who has died aged 83, was an Aberdonian solicitor who rose to be chairman of ICI – and to preside over the demerger ...
  63. [63]
    [PDF] AstraZeneca PLC Half Year Results 1999 - Hugin Online
    Aug 2, 1999 · Astra Tech and Salick Health Care increased sales by 17 and 16 per cent respectively. ... the unaudited pro forma profit and loss figures for 1998 ...Missing: revenue | Show results with:revenue
  64. [64]
    Drug Approval Package: Crestor (Rosuvastatin Calcium) NDA ...
    Jan 29, 2004 · Crestor (Rosuvastatin Calcium) Tablets Company: Astra Zeneca Pharmaceuticals Application No.: 021366. Approval Date: 8/13/2003 ; Medical Review(s)
  65. [65]
    [PDF] AstraZeneca - Annual Report & Form 20-F 2000 - ddd-UAB
    ... AstraZeneca Ordinary. Shares on 10 November 2000 under either the Zeneca 1993 Senior Staff Share Option Scheme, the Zeneca 1994 Executive Share. Option Scheme ...
  66. [66]
    Untitled
    Zoladex sales $1.1 billion, unchanged from the previous year. > Casodex sales $579 million, down 34%, as a result of generic competition in the US, Western ...
  67. [67]
    Novartis, AstraZeneca Merge Agribusinesses, Form Syngenta AG
    Novartis' Crop Protection and Seeds businesses and Zeneca Agrochemicals to create Syngenta AG, an agribusiness company with combined 1998 sales of US$7.9 ...